Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

医学 耐受性 免疫原性 不利影响 接种疫苗 病毒学 内科学 免疫学 抗体 安慰剂 随机对照试验 血清转化 重组DNA
作者
Fengcai Zhu,Yuhua Li,Xuhua Guan,Lihua Hou,Wenjuan Wang,Jingxin Li,Shipo Wu,Busen Wang,Xiaolong Yang,Lei Wang,Siyue Jia,Hu-Dachuan Jiang,Ling Wang,Tao Jiang,Yi Hu,Jin-Bo Gou,Shabei Xu,Hong Shang,Xuewen Wang,Wei Wang,Wei Chen
出处
期刊:The Lancet [Elsevier BV]
卷期号:395 (10240): 1845-1854 被引量:956
标识
DOI:10.1016/s0140-6736(20)31208-3
摘要

A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain.We did a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine in Wuhan, China. Healthy adults aged between 18 and 60 years were sequentially enrolled and allocated to one of three dose groups (5 × 1010, 1 × 1011, and 1·5 × 1011 viral particles) to receive an intramuscular injection of vaccine. The primary outcome was adverse events in the 7 days post-vaccination. Safety was assessed over 28 days post-vaccination. Specific antibodies were measured with ELISA, and the neutralising antibody responses induced by vaccination were detected with SARS-CoV-2 virus neutralisation and pseudovirus neutralisation tests. T-cell responses were assessed by enzyme-linked immunospot and flow-cytometry assays. This study is registered with ClinicalTrials.gov, NCT04313127.Between March 16 and March 27, 2020, we screened 195 individuals for eligibility. Of them, 108 participants (51% male, 49% female; mean age 36·3 years) were recruited and received the low dose (n=36), middle dose (n=36), or high dose (n=36) of the vaccine. All enrolled participants were included in the analysis. At least one adverse reaction within the first 7 days after the vaccination was reported in 30 (83%) participants in the low dose group, 30 (83%) participants in the middle dose group, and 27 (75%) participants in the high dose group. The most common injection site adverse reaction was pain, which was reported in 58 (54%) vaccine recipients, and the most commonly reported systematic adverse reactions were fever (50 [46%]), fatigue (47 [44%]), headache (42 [39%]), and muscle pain (18 [17%]. Most adverse reactions that were reported in all dose groups were mild or moderate in severity. No serious adverse event was noted within 28 days post-vaccination. ELISA antibodies and neutralising antibodies increased significantly at day 14, and peaked 28 days post-vaccination. Specific T-cell response peaked at day 14 post-vaccination.The Ad5 vectored COVID-19 vaccine is tolerable and immunogenic at 28 days post-vaccination. Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy adults, and rapid specific T-cell responses were noted from day 14 post-vaccination. Our findings suggest that the Ad5 vectored COVID-19 vaccine warrants further investigation.National Key R&D Program of China, National Science and Technology Major Project, and CanSino Biologics.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
希望天下0贩的0应助kk子采纳,获得10
刚刚
丰富的不惜完成签到,获得积分10
2秒前
票子发布了新的文献求助10
2秒前
华仔应助魏莱采纳,获得10
2秒前
F123发布了新的文献求助10
3秒前
shen发布了新的文献求助10
4秒前
4秒前
苗觉觉完成签到,获得积分10
5秒前
帕金森完成签到,获得积分10
6秒前
活力的妙芙完成签到,获得积分10
6秒前
赘婿应助疯子魔煞采纳,获得10
7秒前
橙橙橙完成签到,获得积分10
7秒前
7秒前
你好CDY完成签到,获得积分10
8秒前
8秒前
8秒前
万能图书馆应助希尔伯特采纳,获得10
8秒前
我是老大应助123采纳,获得10
9秒前
芒果小鹌鹑完成签到,获得积分10
10秒前
上官若男应助F123采纳,获得10
11秒前
Singularity应助邢文瑞采纳,获得10
12秒前
c123发布了新的文献求助10
13秒前
嘉嘉琦发布了新的文献求助10
14秒前
wanci应助QWDSA采纳,获得10
16秒前
16秒前
愉快静曼发布了新的文献求助10
19秒前
乐乐乐乐乐乐应助科学家采纳,获得10
20秒前
99完成签到,获得积分10
20秒前
20秒前
友好傲白完成签到,获得积分10
20秒前
FL完成签到 ,获得积分10
21秒前
量子星尘发布了新的文献求助10
22秒前
清新的绿海完成签到,获得积分10
22秒前
山色青完成签到,获得积分10
23秒前
23秒前
ya完成签到,获得积分10
23秒前
等风来完成签到 ,获得积分10
24秒前
疯子魔煞完成签到,获得积分10
24秒前
执着的招牌完成签到,获得积分10
24秒前
不着四六的岁月完成签到,获得积分10
25秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038446
求助须知:如何正确求助?哪些是违规求助? 3576149
关于积分的说明 11374627
捐赠科研通 3305875
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892680
科研通“疑难数据库(出版商)”最低求助积分说明 815048